Skip to main content
. Author manuscript; available in PMC: 2013 Sep 16.
Published in final edited form as: Cancer Res. 2011 Oct 18;71(24):7608–7616. doi: 10.1158/0008-5472.CAN-11-1144

Figure 4. Chol-anti-miR-221 cellular activity and localization in orthotopically implanted hepatocellular carcinoma.

Figure 4

Mice orthotopically implanted with hepatocellular carcinoma were injected via the tail vein with 3 daily doses of 60 mg/kg chol-anti-miR-221 or cholesterol-labeled scrambled control oligonucleotide (chol-SC). Mice were sacrificed 7 days after receiving the initial dose. Ki-67 staining in the tumors of mice treated with 60 mg/kg chol-SC oligo (A) or chol-anti-miR-221 (B). In situ hybridization using probes to anti-miR-221 (C) or endogenous miR-221 (D) was performed in the tumors of the mice treated with chol-anti-miR-221 (C and D) or chol-SC oligo (D, insert). Sections were counterstained with nuclear fast red dye. H&E staining in the tumors of mice treated with 60 mg/kg chol-SC oligo (E) or chol-anti-miR-221 (F). The H&E shows the highly anaplastic tumor cells (large arrow) invading the adjacent liver (small arrow).